Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 10, 2012, BG Medicine, Inc. (the "Company") received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("NASDAQ") notifying the Company that for the preceding 30 consecutive business days, the Company's Market Value of Listed Securities ("MVLS") had closed below the minimum $50,000,000 requirement for continued listing on The NASDAQ Global Market, set forth in NASDAQ Listing Rule 5450(b)(2)(A). The notice has no immediate effect on the listing of the Company's common stock and the common stock will continue to trade on The NASDAQ Global Market under the symbol "BGMD" at this time.
In accordance with NASDAQ Listing Rule 5810(c)(3)(C), the Company has a grace period of 180 calendar days, or until June 10, 2013, to regain compliance with NASDAQ Listing Rule 5450(b)(2)(A). Compliance can be achieved automatically and without further action if the Company's MVLS closes at $50,000,000 or more for at least 10 consecutive business days at any time during the 180-day compliance period.